MIP on penicillin derivatives impacting gross margins
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
ALKEMLABORATORIES / Q3-FY26 / risks
Keep the risk register visible.
Alkem Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Occlutech integration and execution risk
Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.
Denosumab litigation delay
US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.
Trade generic business headwinds
Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.